View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Dashboards
  2. Surveys
May 31, 2021

COVID-19 pandemic fuelled transition towards decentralised clinical trials: Survey

The ongoing COVID-19 pandemic has led to significant changes in ways clinical trials are performed and accelerated the adoption of decentralised clinical trials (DCTs).

GlobalData conducted a survey to assess the prospective growth in the post-pandemic DCT use.

Around 67% of the surveyed respondents, who had never used DCTs before, said that they intend to transit from traditional trials now due to the pandemic.

COVID-19 pandemic fuelled transition towards DCT

Is COVID-19 the Reason You Will Begin Using Decentralised Trials for the First time?

In the Rest of World (RoW) region, around 50% of the respondents highlighted COVID-19 as the biggest reason for the switch.

The figure stood at 47%, 46% and 36% in North America, Asia Pacific and Europe regions, respectively.

The analysis is based on responses received from the GlobalData, Coronavirus Survey – Pharmaceutical Imports/Exports and Supply Chain survey- fielded between 04 June 2020 to 22 June 2020.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology